# Efficacy of Favipiravir Against Ebola (JIKI)

> **NCT02329054** · PHASE2 · COMPLETED · sponsor: **Institut National de la Santé Et de la Recherche Médicale, France** · enrollment: 126 (actual)

## Conditions studied

- Ebola Virus Disease

## Interventions

- **DRUG:** Favipiravir

## Key facts

- **NCT ID:** NCT02329054
- **Lead sponsor:** Institut National de la Santé Et de la Recherche Médicale, France
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12
- **Primary completion:** 2015-05
- **Final completion:** 2015-09
- **Target enrollment:** 126 (ACTUAL)
- **Last updated:** 2025-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02329054

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02329054, "Efficacy of Favipiravir Against Ebola (JIKI)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02329054. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*